Surotomycin

[AndyShax]

New drug from Cubist Pharmaceuticals in Phase 3 clinical trials, trials expected to conclude in 2014.
http://www.cubist.com/products/cdad

Following safety and pharmacokinetic studies in healthy human volunteers, Cubist began a Phase 2 study in April 2010 to assess the safety and efficacy of surotomycin in patients with CDAD, in particular to assess its ability to reduce relapse rates. In this trial of 209 patients, two different doses of surotomycin were studied and compared with oral vancomycin. The higher dose demonstrated a high clinical cure rate as evidenced by resolution of diarrhea, comparable to oral vancomycin. The most interesting results in this study, however, relate to recurrence rates. The percent of patients who had an initial response to treatment but who subsequently had a recurrence or relapse was 36 percent in the oral vancomycin arm and was 17 percent in the surotomycin 250mg treatment group — about a 50% reduction in relapse rate, which was statistically significant.

[AllisS]

Andy, I posted the link to this article in Media Reports just now. Please send future links to media articles and journal reports to me or Mlbbarry. Thanks!